Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 13/20 | 0.61 |
| ▸ | RAB9A | P51151 | 13/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.59 |
| ▸ | RELA | Q04206 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6719749 | 1.00 | NPC1 (0.61) | NPC1RAB9AMEN1KMT2ANFKB1 | |
| SCHEMBL13114770 | 0.83 | NPC1 (0.61) | NPC1RAB9AMEN1KMT2ANFKB1 | |
| SCHEMBL8338028 | 0.82 | NPC1 (0.47) | NPC1RAB9AMEN1KMT2ANFKB1 | |
| SCHEMBL6718053 | 0.81 | NPC1 (0.58) | NPC1RAB9AMEN1KMT2ANFKB1 | |
| SCHEMBL19074543 | 0.77 | POLB (0.66) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4982071 | 0.77 | POLB (0.66) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6716026 | 0.77 | ROCK2 (0.73) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4115937 | 0.76 | NPC1 (1.00) | NPC1RAB9AMEN1KMT2ANFKB1 | |
| SCHEMBL14511446 | 0.76 | KMT2A (0.69) | NPC1RAB9AMEN1KMT2ANFKB1 | |
| SCHEMBL31054230 | 0.76 | NPC1 (1.00) | NPC1RAB9AMEN1KMT2ANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152741-A1 | Arylglycine derivatives and their use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
| WO-2004022528-A2 | ARYLGLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS | NPS ALLELIX CORP. (CA) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152741-A1 | Arylglycine derivatives and their use as glycine transport inhibitors | SLC1A2, SLC1A1, SLC7A11 | NPC1 119/4885RAB9A 1608/4885MEN1 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.